IN2014MN02090A - - Google Patents

Info

Publication number
IN2014MN02090A
IN2014MN02090A IN2090MUN2014A IN2014MN02090A IN 2014MN02090 A IN2014MN02090 A IN 2014MN02090A IN 2090MUN2014 A IN2090MUN2014 A IN 2090MUN2014A IN 2014MN02090 A IN2014MN02090 A IN 2014MN02090A
Authority
IN
India
Prior art keywords
brain
medicine
anesthetic
alleviate
prevent
Prior art date
Application number
Other languages
English (en)
Inventor
Tomiei Kazama
Yasushi Satoh
Ryuji Yonamine
Original Assignee
Maruishi Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruishi Pharma filed Critical Maruishi Pharma
Publication of IN2014MN02090A publication Critical patent/IN2014MN02090A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/08Ethers or acetals acyclic, e.g. paraformaldehyde
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2090MUN2014 2012-05-31 2013-05-30 IN2014MN02090A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012125535 2012-05-31
PCT/JP2013/065094 WO2013180240A1 (ja) 2012-05-31 2013-05-30 全身麻酔薬と、水素とを組み合わせてなる、医薬

Publications (1)

Publication Number Publication Date
IN2014MN02090A true IN2014MN02090A (pt) 2015-09-04

Family

ID=49673427

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2090MUN2014 IN2014MN02090A (pt) 2012-05-31 2013-05-30

Country Status (16)

Country Link
US (1) US20150079197A1 (pt)
EP (1) EP2857026A4 (pt)
JP (1) JP6168420B2 (pt)
KR (1) KR20150018832A (pt)
CN (1) CN104394873A (pt)
AU (1) AU2013268366A1 (pt)
BR (1) BR112014029260A2 (pt)
CA (1) CA2874579A1 (pt)
HK (1) HK1205450A1 (pt)
IL (1) IL235718A0 (pt)
IN (1) IN2014MN02090A (pt)
MX (1) MX2014014543A (pt)
NZ (1) NZ701553A (pt)
RU (1) RU2014152690A (pt)
SG (1) SG11201407489TA (pt)
WO (1) WO2013180240A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6253029B2 (ja) * 2015-01-21 2017-12-27 大陽日酸株式会社 麻酔器用取付キット
US20180338995A1 (en) * 2017-05-23 2018-11-29 Perricone Hydrogen Water Company, Llc Systems and methods for treatments using hydrogen and/or noble gases
US11129848B2 (en) * 2017-08-08 2021-09-28 Perricone Hydrogen Water Company, Llc Medication enhancement using hydrogen
EP3814502A4 (en) * 2018-06-29 2022-10-05 John Mansell COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANESTHESIA-RELATED NEUROTOXICITY
US11123365B2 (en) 2019-11-18 2021-09-21 Perricone Hydrogen Water Company, Llc Compositions comprising palmitoylethanolamide and hydrogen water, and methods thereof
JP7019910B2 (ja) * 2020-07-21 2022-02-16 MiZ株式会社 薬の副作用、薬の副作用に関連する症状、および/または、治療に伴う副作用を予防および/または改善するための組成物
CN117861037A (zh) * 2022-10-11 2024-04-12 上海氢医医疗科技有限公司 氢气吸入治疗自闭症

Also Published As

Publication number Publication date
EP2857026A1 (en) 2015-04-08
CA2874579A1 (en) 2013-12-05
SG11201407489TA (en) 2014-12-30
BR112014029260A2 (pt) 2017-06-27
HK1205450A1 (en) 2015-12-18
JP6168420B2 (ja) 2017-07-26
RU2014152690A (ru) 2016-07-20
AU2013268366A1 (en) 2015-03-19
JPWO2013180240A1 (ja) 2016-01-21
CN104394873A (zh) 2015-03-04
NZ701553A (en) 2016-06-24
EP2857026A4 (en) 2015-11-04
MX2014014543A (es) 2015-06-05
IL235718A0 (en) 2015-01-29
WO2013180240A1 (ja) 2013-12-05
US20150079197A1 (en) 2015-03-19
KR20150018832A (ko) 2015-02-24

Similar Documents

Publication Publication Date Title
IN2014MN02090A (pt)
MX2015002292A (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r.
EA201991484A1 (ru) Лекарственные формы энзалутамида
AU349827S (en) Respirator mask
IN2015DN03029A (pt)
IN2015DN03219A (pt)
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
AU349826S (en) Cushion for respirator mask
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
EA201591679A1 (ru) Способ нетоксического лечения абстиненции, вызванной лекарственным средством
HK1208830A1 (en) Drug delivery device for the treatment of patients with respiratory diseases
PH12016501965A1 (en) S1p modulator immediate release dosage regimen
IN2015DN00515A (pt)
AU352986S (en) Nasal dilation device
PL2874600T3 (pl) Kompozycja farmaceutyczna do leczenia chrypki lub bólów gardła.
ECSP12012126A (es) Medicamento
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
BR112015005268A2 (pt) seringa contendo uma composição, em particular farmacêutica, composta por imunoglobulinas, seu método de fabricação e respectivo uso
PH12017500923A1 (en) New dosage and use of a a2a antagonist
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
MX365192B (es) Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.
MX2016007947A (es) Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con caracteristicas melancolicas.
MX356052B (es) Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion.
IN2014KN01772A (pt)